A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral Injection Alone and in Combination With Immune Checkpoint Blockade
Phase of Trial: Phase I
Latest Information Update: 30 Oct 2019
Price : $35 *
At a glance
- Drugs Durvalumab (Primary) ; MRNA 2752 (Primary) ; Tremelimumab (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Moderna Therapeutics
- 16 Oct 2019 Planned number of patients changed from 130 to 126.
- 16 Oct 2019 Planned End Date changed from 1 Nov 2021 to 1 Jun 2021.
- 16 Oct 2019 Planned primary completion date changed from 1 Aug 2020 to 1 Jun 2020.